Breaking News

Takeda Enters License Agreement with HUTCHMED for Fruquintinib

Fruquintinib offers a potential new treatment option for patients with refractory metastatic colorectal cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda has entered into an exclusive licensing agreement with HUTCHMED (China) Ltd. and its subsidiary HUTCHMED Ltd., for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.   Approved in China in 2018, fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, 2 and 3. Fruquintinib is orally administered and has the potential to be used across subtypes of refractory metastatic co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters